Navigation Links
Lidoderm for pain removal in Osteoarthritis

The study was conducted to find out effective treatment for patients having pain due osteoarthritis in one or both knees. //

The treatment tested was providing one full Lidoderm patch in the front of the knee and one third patch on the back of the affected knee. The study result showed that after six weeks of treatment majority of the group of people who underwent the treatment reported about 30% pain relief or more. To the other group the treatment was done with Celebrex(R) for knee pain associated with osteoarthritis. This group also reported that a majority experienced 30% or more relief in the pain intensity.

Lidoderm is an approved pain relief agent that uses a lidocaine patch 5%. The patch produces analgesic effects by penetrating the epidermal and dermal layers of the skin, but need only to be applied on intact skin. The FDA approves up to three patches of Lidoderm applied to a total of 12 hrs in a 24 hrs period. Its efficacy in pain removal except for in post-herpetic neuralgia was not known before the present study.

The results of the study came out in a press release by the firm Endo Pharmaceuticals in 24th Annual Scientific Meeting of the American Pain Society.


'"/>




Page: 1

Related medicine news :

1. Lose stomach for Life....Preventive removal of stomach saves the risk of cancer
2. A promising treatment for wart removal
3. Nigerian girl recovering well after removal of brain tumor
4. Ovary removal to lead to Dementia
5. Pro-reservation body seeks removal of AIIMS Director
6. Doctors ruminate over organ removal principles
7. Ovary removal linked with Early Death in Younger Women
8. New device for discerning Osteoarthritis
9. Osteoarthritis and Estrogen are connected
10. Hyaluronan supplementation therapy for Knee Osteoarthritis
11. Leech Therapy for Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading ... sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a ... operations. With this platform, initializing devices and importing studies are just one-click operations. ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating ... mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh ... to partner with Cupron® to provide customers with a game changing chair that ...
(Date:5/26/2017)... Abilene, Texas (PRWEB) , ... May 26, 2017 , ... ... released a new publication this week that is focusing on the Peace Agreements being ... begun his Middle East sprint in a race to try to speed up peace ...
(Date:5/26/2017)... ... ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in wisdom teeth extraction ... options. If a Bay Area patient has to search for a second opinion before ... in-network provider for a second opinion can ensure a patient receives the full benefits ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
Breaking Medicine Technology: